References
- Abraham, M. J., Murtola, T., Schulz, R., Páll, S., Smith, J. C., Hess, B., & Lindahl, E. (2015). Gromacs: High performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX, 1-2, 19–25. https://doi.org/https://doi.org/10.1016/j.softx.2015.06.001
- Adedeji, A. O., Severson, W., Jonsson, C., Singh, K., Weiss, S. R., & Sarafianos, S. G. (2013). Novel inhibitors of severe acute respiratory syndrome coronavirus entry that act by three distinct mechanisms. Journal of Virology, 87(14), 8017–8028. https://doi.org/https://doi.org/10.1128/JVI.00998-13
- Cai, Y., Liu, Y., & Zhang, X. (2007). Suppression of coronavirus replication by inhibition of the MEK signaling pathway. Journal of Virology, 81(2), 446–456. https://doi.org/https://doi.org/10.1128/JVI.01705-06
- Cant, R., Dalgleish, A. G., & Allen, R. L. (2017). Naltrexone inhibits IL-6 and TNFα production in human immune cell subsets following stimulation with ligands for intracellular toll-like receptors. Frontiers in Immunology, 8, 809https://doi.org/https://doi.org/10.3389/fimmu.2017.00809
- Coperchini, F., Chiovato, L., Croce, L., Magri, F., & Rotondi, M. (2020). The cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system. Cytokine & Growth Factor Reviews. https://doi.org/https://doi.org/10.1016/j.cytogfr.2020.05.003
- Cornish, J. W., Metzger, D., Woody, G. E., Wilson, D., McLellan, A. T., Vandergrift, B., & O'Brien, C. P. (1997). Naltrexone pharmacotherapy for opioid dependent federal probationers. Journal of Substance Abuse Treatment, 14(6), 529–534. https://doi.org/https://doi.org/10.1016/S0740-5472(97)00020-2
- Dehury, B., Behera, S. K., & Mahapatra, N. (2017). Structural dynamics of Casein Kinase I (CKI) from malarial parasite Plasmodium falciparum (Isolate 3D7): Insights from theoretical modelling and molecular simulations. Journal of Molecular Graphics & Modelling, 71, 154–166. https://doi.org/https://doi.org/10.1016/j.jmgm.2016.11.012
- Dehury, B., Patra, M. C., Maharana, J., Sahu, J., Sen, P., Modi, M. K., Choudhury, M. D., & Barooah, M. (2014). Structure-based computational study of two disease resistance gene homologues (Hm1 and Hm2) in Maize (Zea mays L.) with implications in plant-pathogen interactions. PLoS One, 9(5), e97852. https://doi.org/https://doi.org/10.1371/journal.pone.0097852
- Dogra, S., Kar, A. K., Girdhar, K., Daniel, P. V., Chatterjee, S., Choubey, A., Ghosh, S., Patnaik, S., Ghosh, D., & Mondal, P. (2019). Zinc oxide nanoparticles attenuate hepatic steatosis development in high-fat-diet fed mice through activated AMPK signaling axis. Nanomedicine : nanotechnology, Biology, and Medicine, 17, 210–222. https://doi.org/https://doi.org/10.1016/j.nano.2019.01.013
- Fang, L., Karakiulakis, G., & Roth, M. (2020). Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?. The Lancet. Respiratory Medicine, 8(4), e21. https://doi.org/https://doi.org/10.1016/S2213-2600(20)30116-8
- Girdhar, K., Dehury, B., Kumar Singh, M., Daniel, V. P., Choubey, A., Dogra, S., Kumar, S., & Mondal, P. (2019). Novel insights into the dynamics behavior of glucagon-like peptide-1 receptor with its small molecule agonists. Journal of Biomolecular Structure & Dynamics, 37(15), 3976–3986. https://doi.org/https://doi.org/10.1080/07391102.2018.1532818
- Gold, M. S., Dackis, C. A., Pottash, A. L., Sternbach, H. H., Annitto, W. J., Martin, D., & Dackis, M. P. (1982). Naltrexone, opiate addiction, and endorphins. Med Res Rev, 2(3), 211–246. https://doi.org/https://doi.org/10.1002/med.2610020302
- Gonzalez, J. P., & Brogden, R. N. (1988). Naltrexone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence. Drugs, 35(3), 192–213. https://doi.org/https://doi.org/10.2165/00003495-198835030-00002
- Hersoug, L.-G., Møller, P., & Loft, S. (2016). Gut microbiota-derived lipopolysaccharide uptake and trafficking to adipose tissue: Implications for inflammation and obesity. Obesity Reviews : An Official Journal of the International Association for the Study of Obesity, 17(4), 297–312. https://doi.org/https://doi.org/10.1111/obr.12370
- Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N.-H., Nitsche, A., Müller, M. A., Drosten, C., & Pöhlmann, S. (2020). SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell, 181(2), 271–280.e8. https://doi.org/https://doi.org/10.1016/j.cell.2020.02.052
- Hussain, A. (2020). Targeting SARS-CoV2 spike protein receptor binding domain by therapeutic antibodies. Biomedicine and Pharmacotherapy, 130.
- Hutchinson, M. R., Zhang, Y., Brown, K., Coats, B. D., Shridhar, M., Sholar, P. W., Patel, S. J., Crysdale, N. Y., Harrison, J. A., Maier, S. F., Rice, K. C., & Watkins, L. R. (2008). Non-stereoselective reversal of neuropathic pain by naloxone and naltrexone: Involvement of toll-like receptor 4 (TLR4). The European Journal of Neuroscience, 28(1), 20–29. https://doi.org/https://doi.org/10.1111/j.1460-9568.2008.06321.x
- Lan, J., Ge, J., Yu, J., Shan, S., Zhou, H., Fan, S., Zhang, Q., Shi, X., Wang, Q., Zhang, L., & Wang, X. (2020). Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature, 581(7807), 215–220. https://doi.org/https://doi.org/10.1038/s41586-020-2180-5
- Li, Z., You, Y., Griffin, N., Feng, J., & Shan, F. (2018). Low-dose naltrexone (LDN): A promising treatment in immune-related diseases and cancer therapy. International Immunopharmacology, 61, 178–184. https://doi.org/https://doi.org/10.1016/j.intimp.2018.05.020
- Livak, K. J., & Schmittgen, T. D. (2001). Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods (San Diego, Calif.).), 25(4), 402–408. https://doi.org/https://doi.org/10.1006/meth.2001.1262
- Low-Dose Naltrexone for Pruritus in Systemic Sclerosis. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3171757/. (Accessed 24th May 2020)
- Lu, R., Zhao, X., Li, J., Niu, P., Yang, B., Wu, H., Wang, W., Song, H., Huang, B., Zhu, N., Bi, Y., Ma, X., Zhan, F., Wang, L., Hu, T., Zhou, H., Hu, Z., Zhou, W., Zhao, L., … Tan, W. (2020). Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding. Lancet (London, England), 395(10224), 565–574. https://doi.org/https://doi.org/10.1016/S0140-6736(20)30251-8
- Madjid, M., Safavi-Naeini, P., Solomon, S. D., & Vardeny, O. (2020). Potential effects of coronaviruses on the cardiovascular system: A review. JAMA Cardiology, 5(7), 831. https://doi.org/https://doi.org/10.1001/jamacardio.2020.1286
- Mizutani, T. (2010). Signaling pathways of SARS-CoV in vitro and in vivo. Molecular Biology of the SARS-Coronavirus (pp. 305–322). Heidelberg, Berlin: Springer. https://doi.org/https://doi.org/10.1007/978-3-642-03683-5_19
- Morris, G. M., Huey, R., Lindstrom, W., Sanner, M. F., Belew, R. K., Goodsell, D. S., & Olson, A. J. (2009). Software news and updates AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. Journal of Computational Chemistry, 30(16), 2785–2791. https://doi.org/https://doi.org/10.1002/jcc.21256
- Parkitny, L., & Younger, J. (2017). Reduced pro-inflammatory cytokines after eight weeks of low-dose naltrexone for fibromyalgia. Biomedicines, 5(4), 16. https://doi.org/https://doi.org/10.3390/biomedicines5020016
- Patil, S. (2020). Drug repurposing for Covid-19: Discovery of potential small-molecule inhibitors of spike protein-ACE2 receptor interaction through virtual screening and consensus scoring. https://doi.org/https://doi.org/10.26434/CHEMRXIV.12482435.V1
- Rahmati, M., & Moosavi, M. A. (2020). Letter to the editor cytokine-targeted therapy in severely ill COVID-19 patients: Options and cautions. Eurasian Journal of Medicine and Oncology, 4, 179–180.
- Ramos-Benitez, M. J., Ruiz-Jimenez, C., Rosado-Franco, J. J., Ramos-Pérez, W. D., Mendez, L. B., Osuna, A., & Espino, A. M. (2018). Fh15 blocks the lipopolysaccharide-induced cytokine storm while modulating peritoneal macrophage migration and CD38 expression within spleen macrophages in a mouse model of septic shock. mSphere, 3(6) e00548-18. https://doi.org/https://doi.org/10.1128/mSphere.00548-18
- Stockman, L. J., Bellamy, R., & Garner, P. (2006). SARS: Systematic Review of Treatment Effects. PLoS Medicine, 3(9), e343https://doi.org/https://doi.org/10.1371/journal.pmed.0030343
- Tanaka, T., Narazaki, M., & Kishimoto, T. (2016). Immunotherapeutic implications of IL-6 blockade for cytokine storm. Immunotherapy, 8(8), 959–970. https://doi.org/https://doi.org/10.2217/imt-2016-0020
- The Uses of Low-Dose Naltrexone in Clinical Practice. (2020). Natural Medicine Journal. https://www.naturalmedicinejournal.com/journal/2018-04/uses-low-dose-naltrexone-clinical-practice.
- Toljan, K., & Vrooman, B. (2018). Low-Dose Naltrexone (LDN)—Review of Therapeutic Utilization. Medical Sciences, 6(4), 82. https://doi.org/https://doi.org/10.3390/medsci6040082
- Vanommeslaeghe, K., & MacKerell, A. D. (2012). Automation of the CHARMM general force field (CGenFF) I: Bond perception and atom typing. Journal of Chemical Information and Modeling, 52(12), 3144–3154. https://doi.org/https://doi.org/10.1021/ci300363c
- Vickers, A. P., & Jolly, A. (2006). Naltrexone and problems in pain management. BMJ (Clinical Research ed.).), 332(7534), 132–133. https://doi.org/https://doi.org/10.1136/bmj.332.7534.132
- Walls, A. C., Park, Y.-J., Tortorici, M. A., Wall, A., McGuire, A. T., & Veesler, D. (2020). Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell, 181(2), 281–292.e6. https://doi.org/https://doi.org/10.1016/j.cell.2020.02.058
- Wang, T., Du, Z., Zhu, F., Cao, Z., An, Y., Gao, Y., & Jiang, B. (2020). Comorbidities and multi-organ injuries in the treatment of COVID-19. The Lancet, 395(10228), e52. https://doi.org/https://doi.org/10.1016/S0140-6736(20)30558-4
- Wang, X., Zhang, Y., Peng, Y., Hutchinson, M. R., Rice, K. C., Yin, H., & Watkins, L. R. (2016). Pharmacological characterization of the opioid inactive isomers (+)-naltrexone and (+)-naloxone as antagonists of toll-like receptor 4. British Journal of Pharmacology, 173(5), 856–869. https://doi.org/https://doi.org/10.1111/bph.13394
- Wu, D., & Yang, X. O. (2020). TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib. Journal of Microbiology, Immunology and Infection, 108(1),17-41. https://doi.org/https://doi.org/10.1016/j.jmii.2020.03.005
- Wu, F., Zhao, S., Yu, B., Chen, Y.-M., Wang, W., Song, Z.-G., Hu, Y., Tao, Z.-W., Tian, J.-H., Pei, Y.-Y., Yuan, M.-L., Zhang, Y.-L., Dai, F.-H., Liu, Y., Wang, Q.-M., Zheng, J.-J., Xu, L., Holmes, E. C., & Zhang, Y.-Z. (2020). A new coronavirus associated with human respiratory disease in China. Nature, 579(7798), 265–269. https://doi.org/https://doi.org/10.1038/s41586-020-2008-3
- Younger, J., Parkitny, L., & McLain, D. (2014). The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clinical Rheumatology, 33(4), 451–459. https://doi.org/https://doi.org/10.1007/s10067-014-2517-2
- Zaim, S., Chong, J. H., Sankaranarayanan, V., & Harky, A. (2020). COVID-19 and multiorgan response. Current Problems in Cardiology, 45(8), 100618. https://doi.org/https://doi.org/10.1016/j.cpcardiol.2020.100618
- Zha, L. (2020). Corticosteroid treatment of patients with coronavirus disease 2019 (COVID‐19. Medical Journal of Australia, 212, 416–420.
- Zhang, W., Zhao, Y., Zhang, F., Wang, Q., Li, T., Liu, Z., Wang, J., Qin, Y., Zhang, X., Yan, X., Zeng, X., & Zhang, S. (2020). The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The experience of clinical immunologists from China. Clinical Immunology (Orlando, Fla.), 214, 108393. https://doi.org/https://doi.org/10.1016/j.clim.2020.
- Zhao, M. (2020). Cytokine storm and immunomodulatory therapy in COVID-19: Role of chloroquine and anti-IL-6 monoclonal antibodies. International Journal of Antimicrobial Agents, 55(6),105982. https://doi.org/https://doi.org/10.1016/j.ijantimicag.2020.105982